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Summary
Human peripheral blood eosinophils released eosinophil survival-enhancing activitywhen stimulated
with the calcium ionophore, ionomycin . The release of activity was detected as early as 3 h after
stimulation and was inhibited by an immunomodulating agent, cyclosporin A . The survival-
enhancing activity was completely abolished by treatment with anti-interleukin 3 (IL3) and
anti-granulocyte/macrophage colony-stimulating factor (GM-CSF) monoclonal antibodies .
Moreover, IL-3 and GM-CSF were measurable in ionomycin-stimulated eosinophil supernatants
by immunoassay. Eosinophils produced approximately one-half as much IL3 and one-fifth as
much GM-CSF as ionomycin-stimulated mononuclear cells. Neutrophils also produced 11,3 and
GM-CSF, but the amounts were less than those produced by eosinophils. These observations
suggest a novel role for eosinophils in pathophysiology of allergic inflammation and host defense
mechanisms.
E
osinophils are blood leukocytes associated with helminth
infections and allergic diseases, especiallybronchial asthma,
and may mediate immunity and tissue damage (1) . Several
rytokines, including IL3, 116, and granulocyte/macrophage
colony-stimulating factor (GM-CSF), induce eosinophilopoi-
esis and activate mature peripheral blood eosinophils in vitro
(reviewed in reference 2). Recently, mRNA for these rytokines
was detected in allergen-induced late-phase cutaneous reac-
tions in atopic patients, suggesting that these rytokines play
an important role in allergic inflammation (3) .
Becausehuman peripheral blood eosinophils, despite their
high degree of specialization, retain the ability to synthesize
rytokines such as TGF-ot and IL1 (4, 5), we investigated
whether they can produce IL-3, IL-5, and GM-CSF . We
found that ionomycin-stimulated eosinophils produce GM-
CSF and IL-3 as shown by enhanced eosinophil survival and
by immunochemical measurement .
Cells and Culture Conditions. Eosinophils, neutrophils, and
mononuclear cells were isolated from peripheral blood of healthy
volunteers or patients with mild hay fever by discontinuous Percoll
density gradient as previously described (6) . Purities ofeosinophils
and neutrophils were 391% and 399%, respectively. Con-
taminating cells in the eosinophil preparations were only neutro-
phils and those in the neutrophil preparations were only eosinophils .
Cell viabilities were >98% . Cells were incubated (2 x 10 5 cells
per 0.2 ml per well) in Hybri-Care medium (American Type Cul-
ture Collection, Rockville, MD) supplemented with 50 lAg/ml gen-
tamicin and 10% defined calf serum in 96-well flat-bottomed mi-
crotiter plates (Falcon Labware, Lincoln Park, NJ) with ionomycin
(Calbiochem Corp., San Diego, CA) in the presence or absence
ofPMA (500pg/ml ; Calbiochem Corp.) . After 24 h at 37°C, cell-
free supernatants were harvested and frozen until assayed .
Eosinophil Survival Assay .
￿
To measure eosinophil survival en-
hancing activity (7) in supernatants, eosinophils were freshly iso-
lated from different donors and were cultured (2.5 x 10" cells per
0.2 ml per well) in Hybri-Care medium in the presence (25% ;
vol/vol) of supernatants as described above. After 96 h, cell via-
bility and recovery were counted by staining cells with fluorescein
diacetate and propidium iodide using a hemacytometer and an
epifluorescent microscope. Specific inhibition of eosinophil survival
enhancing activity was tested by incubating supernatants with rat
mAbs against each of the rytokines (8) . Supernatants were treated
with antibodies for 1 h at 4°C and then cultured (12.5% ; vol/vol)
with freshly isolated eosinophils . Preliminary study showed that
these antibodies inhibited eosinophil survival inducedby the corre-
sponding cytokine in a dose-dependent manner. Each of the anti-
bodies specifically neutralized its respective cytokine and showed
no crossreactivity with the other cytokines.
Immunochemical Measurement of Cytokines.
￿
The amounts of
rytokines in the supernatants were measured by immunoenzymetric
assay using rat monoclonal capture antibody followed by nitro-
iodophenyl (NIP)-derivatized detectingmAb. Bound NIPmAb was
detected by rat monoclonal anti-NIP immunoperoxidase conjugate
and developed by peroxidase chromogenic substrate 2,2'-azino-bis
(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma Chemical Co., St .
Louis, MO) plus HZO Z (8) . The threshold sensitivities of assays
were I1r3, 40 pg/ml; IL-5, 30 pg/ml ; and GM-CSF, 20 pg/ml .
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RIA.for Eosinophil-derived Neurotoxin (EDN) .
￿
The EDN levels
in supernatants were measured by RIA to quantitate eosinophil
degranulation, as described previously (9) .
Statistical Analysis.
￿
The data were compared using paired or un-
paired Student's t test .
Results and Discussion
Human peripheral blood eosinophils die within 96 h in
culture without specific cytokines, such as IL-3, IL-5, orGM-
CSF (10) . Treatment with the calcium ionophore, ionomycin,
led to a striking enhancement of eosinophil survival in the
absence of exogenous cytokines (Fig. 1 a) . The response to
ionomycin was dose dependent and was abolished by high
concentrations of ionomycin . Neutrophil survival was not
enhanced by ionomycin.
To determine whether ionomycin directly enhanced eosin-
ophil survival or whether it stimulated eosinophils to pro-
duce rytokines, supernatants from eosinophils exposed to
ionomycin for 24 h were added to freshly isolated eosinophils .
Supernatants from eosinophils stimulated by ionomycin en-
hanced the survival of fresh eosinophils, and the production
offactors that enhanced eosinophil survival was dose-dependent
(Fig . 1 b) . AlthoughPMA (500 pg/ml) alone did not induce
production of eosinophil survival-enhancing factor from eo-
sinophils, it lowered the ionomycin concentrations required
for stimulation. Supernatants from ionomycin-stimulated neu-
trophils also enhanced eosinophil survival (Fig. 1 b), although
to a lesser degree than eosinophils (p < 0.01 at 1 t.M
ionomycin) .
The possibility that neutrophils contaminating the eosin-
ophil preparations were the source of the survival-enhancing
factors was examined . First, 99% pure eosinophils from one
donor responded to ionomycin virtually identically to those
shown in Fig . 1 b . Second, eosinophils isolated by Percoll
gradient centrifugation were further purified by culture with
rhIL-5 (1 ng/ml) for 7 d ; these conditions eliminated neu-
trophils . Eosinophils were >99.8% pure and >85% viable
and produced survival-enhancing activity with a dose-response

























Cytokine Release from Eosinophils and Neutrophils
Figure 2 .
￿
Inhibition ofeosinophil survival-enhancing activityby mAbs
to cytokknns . Supernatants ofeosinophils and neutrophils stimulated with
ionomycin (1 )AM) were treated with antibodies for 1 h at 4°C and cul-
tured with freshly isolated eosinophils. Data are presented as the mean
± SEM from three separate experiments .
sinophils themselves produce eosinophil survival-enhancing
factors .
To determine whether eosinophil survival-enhancing ac-
tivity was due to cytokines, supernatants were treated with
neutralizing antibodies to IL-3, IL-5, or GM-CSF. Anti-IL-3
and anti-GM-CSF each partially inhibited eosinophil survival-
enhancing activity, and, when used together, anti-IL-3 and
anti-GM-CSF completely abolished survival-enhancing ac-
tivity (Fig . 2) . These findings indicate that eosinophil survival-
enhancing activity from ionomycin-stimulated eosinophils and
neutrophils is due to IL-3 and GM-CSF. Moreover, IL-3 and
GM-CSF were measurable in the eosinophil supernatants
(Table 1) . Eosinophils produced about one-halfas much IL-3
and one-fifth as much GM-CSF as mononuclear cells . IL-5
was not detected in supernatants of eosinophils or mononuclear
cells . Neither IL-3, IL-5, nor GM-CSF were measurable in
supernatants from neutrophils, suggesting that neutrophils
produce smaller amounts of cytokines than eosinophils .
Comparison of eosinophil cytokine secretion and eosino-
phil degranulation showed that GM-CSF and IL-3 release
begins 3 h after ionomycin stimulation and reaches high levels





lonomycin-induced survival ofeosinophils (a)
and release of eosinophil survival-enhancing activity from
eosinophils and neutrophils (b) . (a) Eosinophils were in-
cubated with ionomycin. After 96 h, cell viability and
recovery were determined. (b) Eosinophils and neutrophils
were incubated with ionomycin alone (open circles) or with
PMA (-)
￿
ionomycin andPMA (closedcircles) for 24 h. Supernatants
were collected and cultured with eosinophils freshly iso-
lated from different donors. Eosinophil viability was de-
termined after 96 h. Control supernatants from wells with
stimulants, but without cells, were inactive. Data are
presented as mean ± SEM from four (a) and six (b) sepa-
rate experiments .Isolated eosinophils, neutrophils, mononuclear cells, and huffy coat cells
(106 cells/ml) were stimulated with ionomycin (1 AM) in the presence
or absence ofPMA (500 pg/ml) for 24 h . Cell-free supernatants were
assayed for IL-3, IL-5, and GM-CSF by immunochemical measurement
as described in Materials and Methods . In the absence ofionomycin, IL-3
and GM-CSF production by anyof the cell preparations were not mea-
surable. Results (mean ± SEM) from four or six separate experiments
are shown.
Experiments in which the cytokine was detected/total number of
experiments .
ophil granule protein, EDN, occurred during the6-h exposure
of cells to 1 AM ionomycin (<1.5% release of total EDN
release) . By 12 h and clearly at 24 h, appreciable amounts
ofEDNwere released . These results suggest that eosinophil
granule protein releaseandcytokine release are different events.
CyclosporinA is apowerful inhibitor ofcytokine synthesis
from lymphocytes (11) . Here, cyclosporin A completely abol-
ishedcytokine releasefrom both eosinophils and neutrophils
(Fig. 3 b) . CyclosporinA had no toxic effect on cells, as as-
sessed by cell viability, and had no stimulatory or inhibitory
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